Estándar de tratamiento en primera línea de cáncer de páncreas metastásico: ¿ABRAXANE-GEMCITABINA o FOLFIRINOX? - page 3

Primary Endpoint

Conroy T. N Engl J Med 2011;364:1817-25

mOS 11.1m FOLFIRINOX VS. 6.8 m G

mOS 8.7 m NP-G vs. 6.6 m G

Von Hoff DD, N Engl J Med. 2013;369:1691-1703

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2 4,5,6,7,8,9,10,11,12,13,...22